Publications
Detailed Information
Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, Yongjun | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Seol, Hyesil | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.accessioned | 2021-01-31T11:01:00Z | - |
dc.date.available | 2021-01-31T11:01:00Z | - |
dc.date.created | 2020-11-19 | - |
dc.date.created | 2020-11-19 | - |
dc.date.issued | 2014-08 | - |
dc.identifier.citation | Anticancer Research, Vol.34 No.8, pp.4275-4280 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.other | 116765 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172966 | - |
dc.description.abstract | Aim: To identify immunohistochemical (IHC) features associated with sensitivity to lapatinib-plus-capecitabine (LX) and resistance to trastuzumab in human epidermal growth factor receptor (HER)-2-positive metastatic breast cancer. Patients and Methods: Expression levels of estrogen receptor, progesterone receptor, epidermal growth factor receptor, HER2, HER3/phosphorylated HER3 (pHER3), phosphatase and tensin homolog, thymidylate synthase (TYMS), and thymidine phosphorylase by IHC were compared between patients treated with LX following trastuzumab failure. Results: In 35 patients, HER2 was the only biomarker associated with LX treatment outcomes. A high HER2 level was associated with significantly longer survival and a tendency towards longer time-to-progression and higher response rates. Acquisition of trastuzumab resistance was associated with higher pHER3 and TYMS expression. Elevated pHER3 was predictive of superior treatment outcomes. Conclusion: Upregulation of pHER3 and TYMS was associated with trastuzumab resistance. High HER2 and increased pHER3 IHC levels correlated with favourable LX treatment outcomes in patients with HER2-positive metastatic breast cancer. | - |
dc.language | 영어 | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.title | Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.citation.journaltitle | Anticancer Research | - |
dc.identifier.wosid | 000339773400052 | - |
dc.identifier.scopusid | 2-s2.0-84908661348 | - |
dc.citation.endpage | 4280 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 4275 | - |
dc.citation.volume | 34 | - |
dc.identifier.sci | 000339773400052 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | THYMIDYLATE SYNTHASE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | trastuzumab | - |
dc.subject.keywordAuthor | lapatinib | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | HER3 | - |
dc.subject.keywordAuthor | TYMS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.